复方华蟾素口服液抗乙型肝炎病毒体外实验研究 |
| |
引用本文: | 刘庄,傅希贤,张乃临,张国庆,刘丹.复方华蟾素口服液抗乙型肝炎病毒体外实验研究[J].中国中西医结合杂志,1996,16(12):738-740. |
| |
作者姓名: | 刘庄 傅希贤 张乃临 张国庆 刘丹 |
| |
作者单位: | 北京地坛医院,北京医科大学第一附属医院传染病教研室 |
| |
摘 要: | 本研究以乙型肝炎病毒脱氧核糖核酸(HBVDNA)转染细胞系(2.2.15细胞株)为模型,对复方华蟾素口服液体外抗乙型肝炎病毒(HBV)活性进行了研究。结果显示:该药对乙型肝炎表面抗原(HBsAg)和乙型肝炎e抗原(HBeAg)半数抑制剂量(ID50)分别为0.08mg/ml和0.07mg/ml,半数中毒剂量(CD50)为2.5mg/ml,治疗指数(TI)分别为HBsAg31.3、HBeAg35.7
|
关 键 词: | 乙型肝炎病毒 复方华蟾素 口服液 中医药疗法 |
Inhibitory Effects of Co-Cinobufotalin Oral Liquor on Hepatitis B in vitro |
| |
Authors: | LIU Zhuang FU Xi -xian Zhang Nai-lin |
| |
Abstract: | Co-Cinobufotalin Oral Liquor (CCOL) was studied for its ability to inhibit hepatitis B virus DNA replication, HBsAg and HBeAg expression in a HBV-transfected cell line(2.2.15 cell).The result showed that ID50(the drug concentration that inhibits HBsAg or HBeAg secretion by 50%)was 0.08 mg/ml and 0.07 mg/ml on HBsAg and HBeAg respectively. CD50(the drug concentration that reduces cell growth by 50%) was 2.5 mg/ml.TI(therapeutic index)was 31.3 and 35.7 respectively.The present data suggest that CCOL could exert a potent antiviral activity against HBV in vitro.Southern blot showed that CCOL inhibited HBV-DNA replication in a dose-dependent manner. |
| |
Keywords: | hepatitis B virus transfected cell line Co-Cinobufotalin Oral Liquor Southern blot hybridization |
本文献已被 CNKI 维普 等数据库收录! |
| 点击此处可从《中国中西医结合杂志》浏览原始摘要信息 |
| 点击此处可从《中国中西医结合杂志》下载免费的PDF全文 |